Bortezomib (B)

DRUG4 trials

Sponsors

National Cancer Institute (NCI), Sun Yat-sen University, Dana-Farber Cancer Institute, University of Heidelberg Medical Center

Conditions

Lymphoma, Mantle CellMantle Cell LymphomaMetastatic Breast CancerMultiple MyelomaRecurrent Breast Cancer

Phase 1

Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer

RecruitingNCT06900647

Sun Yat-sen UniversityMetastatic Breast Cancer, Recurrent Breast Cancer

Start: 2025-01-01End: 2028-06-30Target: 20Updated: 2025-04-02

Phase 2

EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma

CompletedNCT00114738

National Cancer Institute (NCI)Lymphoma, Mantle Cell, Mantle Cell Lymphoma

Start: 2005-06-15End: 2022-08-11Updated: 2022-10-10

Phase 3

Determination 2 - Isatuximab, Iberdomide, Bortezomib and Dexamethasone Induction, Followed by Risk- and Response-Adapted Consolidation and Maintenance Therapy, in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma

Not yet recruitingNCT07624513

Dana-Farber Cancer InstituteMultiple Myeloma

Start: 2026-06-08End: 2038-03-01Target: 720Updated: 2026-06-03

GMMG-HD11/DSMM XXI/64007957MMY3010

Not yet recruitingNCT07671287

University of Heidelberg Medical CenterMultiple Myeloma

Start: 2026-06-30End: 2033-01-30Target: 399Updated: 2026-06-26

Related Papers

Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma

Blood Advances2022-02-1039 citations

Circulating tumor DNA to predict timing of relapse in mantle cell lymphoma.

Journal of Clinical Oncology2018-05-207 citations

Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients

Blood2013-08-12204 citations